On December 10, 2018 OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, reported that the Company has received a $7.0 million investment at $1.50 per share from Alpha Holdings, Inc. (kosdaq:117670) as part of a fundamental strategic investment centered on the clinical development of OncoSec’s lead immunotherapy product candidate, TAVO (tavokinogene telseplasmid) (Press release, OncoSec Medical, DEC 10, 2018, View Source [SID1234531980]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the stock purchase agreement, Alpha Holdings purchased $7 million worth of shares of common stock from OncoSec at $1.50 per share. The investment was executed on December 6 and completes a commitment to OncoSec by Alpha Holdings to purchase a total value of $15 million shares of common stock priced at $1.50 per share. Further details of the transaction can be found in the Form 8-K filed by the Company describing the agreement.
"We have identified the biotechnology sector and the immunotherapy space in particular as a significant value driver for us moving forward. Specifically, we see tremendous potential in OncoSec’s strategy to turn good drugs into great drugs," said Hee Do Koo, President and Chief Executive Officer of Alpha Holdings. "OncoSec recently released positive preliminary data on TAVO demonstrating significant potential when combined with a checkpoint inhibitor, and we believe their platform has broad applicability to improve patient outcomes by expanding the utility of checkpoint inhibitors across a variety of tumor types."
Alpha Holdings is a leading Korean technology company engaged in the design, development, service and manufacture of system semiconductors, as well as the development of biotechnologies and thermal compound materials. Since 2002, Alpha Holdings has successfully carried out many projects as a major partner of Samsung Advanced Foundry Eco-system (SAFE) of Samsung Electronics. Alpha Holdings, a listed company in the KOSDAQ Market, was founded in 2002 and is headquartered in Seongnam, South Korea.
"Alpha Holdings shares our vision for the potential of our platform and their continued support will be an asset for us as we advance TAVO and our robust pipeline of compounds focused on intratumoral treatment of cancer," said Daniel J. O’Connor, President and Chief Executive Officer of OncoSec. "Having Alpha Holdings as a partner also strengthens our presence in Korea and Asia, important markets for potential opportunities as we move forward."